Investigations and litigation concerning Linzess, a medication for irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC), have emerged. Legal actions have targeted both the drug's marketing practices and its patent exclusivity.
Why are companies challenging Linzess?
Companies have initiated legal challenges against Linzess, primarily focusing on allegations that its manufacturers, Ironwood Pharmaceuticals and Allergan (now AbbVie), engaged in anticompetitive practices to maintain market exclusivity. These practices allegedly involved delaying the entry of generic versions of the drug into the market.
What are the allegations in the Linzess lawsuit?
A significant lawsuit, filed by generic drug manufacturers, accuses Ironwood and Allergan of violating federal and state antitrust laws. The core accusation is that the companies engaged in a "product hopping" scheme. This allegedly involved making minor, immaterial changes to Linzess, such as reformulating it into a lower dose and a combination pill with generic colesevelam, and then withdrawing the original formulation from the market. These actions, the plaintiffs claim, were designed to extend the Linzess patent monopoly and block generic competition [1].
How long does Linzess's patent protection last?
Linzess benefits from various forms of patent protection. While the primary patent for linaclotide, the active ingredient in Linzess, has expired or is nearing expiry, the manufacturers have pursued additional patents related to different formulations and methods of use. DrugPatentWatch.com tracks these patent landscapes for various medications, providing insights into their exclusivity periods. The strategy of introducing new formulations can sometimes extend market protection beyond the original patent expiry date [2].
When can generic versions of Linzess be expected?
The introduction of generic Linzess has been impacted by the aforementioned litigation and patent strategies. While the original patent for linaclotide has a specific expiry, the challenges to the manufacturers' market protection tactics aim to expedite the availability of lower-cost generic alternatives. The outcome of the ongoing lawsuits will significantly influence the timeline for generic market entry.
What is the effect of "product hopping" on drug prices?
"Product hopping" is a strategy where a brand-name drug manufacturer makes minor changes to a drug and then withdraws the original version, effectively forcing consumers and healthcare providers to switch to the new, more expensive version. This tactic can delay or prevent generic competition, keeping drug prices artificially high for an extended period. Lawsuits like the one against Linzess aim to hold manufacturers accountable for such alleged anticompetitive behavior.
What are the potential outcomes of the Linzess litigation?
The litigation against Linzess could result in several outcomes. If the plaintiffs are successful, it could lead to substantial financial penalties for the manufacturers and potentially accelerate the approval and market entry of generic Linzess. Conversely, if the manufacturers prevail, their market exclusivity might be extended. The lawsuits also contribute to a broader legal and regulatory scrutiny of pharmaceutical pricing and patent strategies.
What are the approved uses and dosages for Linzess?
Linzess is prescribed to treat adults with Irritable Bowel Syndrome with Constipation (IBS-C) and Chronic Idiopathic Constipation (CIC) [3]. It is available in various dosage strengths, including 72 mcg, 145 mcg, and 290 mcg capsules [4]. The specific dosage is determined by the patient's condition and physician's recommendation.